Stem Cells International / 2015 / Article / Fig 7

Research Article

Multiple Myeloma Patients at Various Cytogenetic Risks Benefit Differently from Autologous Stem Cell Transplantation as a Consolidation Therapy

Figure 7

Comparison of PFS in the patients of ASCT group and non-ASCT group in the low-risk subgroup. The median PFS was prolonged 17.2 months in ASCT group (34.8 versus 17.6 months, ).